Avram E Denburg
Overview
Explore the profile of Avram E Denburg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duffy C, Hunger S, Bhakta N, Denburg A, Antillon F, Barr R
Cancer
. 2024 Mar;
130(13):2247-2252.
PMID: 38552145
No abstract available.
2.
Gauvreau C, Schreyer L, Gibson P, Koo A, Ungar W, Regier D, et al.
Value Health
. 2024 Mar;
27(7):879-888.
PMID: 38548179
Objectives: A health technology assessment (HTA) does not systematically account for the circumstances and needs of children and youth. To supplement HTA processes, we aimed to develop a child-tailored value...
3.
Hantel A, Spence R, Camacho P, Bradbury A, Denburg A, Jagsi R, et al.
J Clin Oncol
. 2023 Dec;
42(3):358-365.
PMID: 38061010
No abstract available.
4.
Cohen-Gogo S, Denburg A, Villani A, Thacker N, Egan G, Simao Rafael M, et al.
Paediatr Child Health
. 2023 Jul;
28(5):278-284.
PMID: 37484033
Cancer is the leading cause of disease-related death in children, adolescents, and young adults beyond the newborn period in North America. Improving survival rates for patients with hard-to-cure cancer remains...
5.
Petricca K, Kambugu J, Githanga J, Macharia W, Njuguna F, McLigeyo A, et al.
Lancet Oncol
. 2023 Apr;
24(5):563-576.
PMID: 37023781
Background: Access to essential childhood cancer medicines is a core determinant of childhood cancer outcomes. Available evidence, although scarce, suggests that access to these medicines is highly variable across countries,...
6.
Hunter J, Robertson E, Hetherington K, Ziegler D, Marshall G, Kirk J, et al.
J Pers Med
. 2022 Aug;
12(8).
PMID: 36013276
Current literature/guidelines regarding the most appropriate term to communicate a cancer-related disease-causing germline variant in childhood cancer lack consensus. Guidelines also rarely address preferences of patients/families. We aimed to assess...
7.
Denburg A, Fundytus A, Khan M, Howard S, Antillon-Klussmann F, Sengar M, et al.
JCO Glob Oncol
. 2022 Jun;
8:e2200034.
PMID: 35749676
Purpose: Access to essential cancer medicines is a major determinant of childhood cancer outcomes globally. The degree to which pediatric oncologists deem medicines listed on WHO's Model List of Essential...
8.
Zhang Y, Wagner A, Du H, Han T, Gupta S, Denburg A, et al.
Int J Cancer
. 2021 Sep;
150(3):482-490.
PMID: 34536294
Different from less developed countries, 80% of children with cancers in the United States are cured. Traditional chemotherapy drugs are the mainstay of therapies; new targeted medications have become available...
9.
Boateng R, Petricca K, Tang B, Parikh S, SinQuee-Brown C, Alexis C, et al.
Lancet Glob Health
. 2021 Aug;
9(9):e1314-e1324.
PMID: 34416215
Background: Equitable access to essential medicines is a key facet of childhood cancer care, recognised by WHO as vital to improved childhood cancer outcomes globally. In the Caribbean, childhood cancer...
10.
Hughes T, Empringham B, Wagner A, Ward Z, Yeh J, Gupta S, et al.
Cancer
. 2021 Apr;
127(16):2990-3001.
PMID: 33844270
Background: Childhood cancer outcomes in low-income and middle-income countries have not kept pace with advances in care and survival in high-income countries. A contributing factor to this survival gap is...